Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Khorana Risk Score for Venous Thromboembolism in Cancer Patients

    Predicts risk of VTE for cancer patients depending on type of cancer and other factors.
    Favorite
    When to Use
    Pearls/Pitfalls
    Why Use

    Patients with a cancer diagnosis starting chemotherapy.

    • Categorizes cancer patients for VTE risk.
    • Higher risk cohorts (e.g. inpatients, lower performance scores) have even higher risks than shown.
    • Most validations were completed in outpatients settings with higher risk cancer patients.

    Predicting VTE in cancer patients is complicated and likely improved by a scoring system.

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Advice

    The Khorana Risk Score stratifies risk well. In outpatients, VTE risk remains relatively low (~10%) even in the highest score groups.

    Management

    At least one author group has applied a binary version of the Khorana Risk Score in practice, using the result for clinical decision making.

    Critical Actions

    The Khorana Risk Score requires multiple laboratory variables, and it may not stratify as consistently or accurately in higher risk patients and those with cancers not indicated in the score.

    Dr. Alok Khorana

    About the Creator

    Alok A. Khorana, MD is a professor of medicine at the Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, and the Sondra and Stephen Hardis Chair in Oncology Research. He is currently the vice-chair for clinical services of the Taussig Cancer Institute and director of the Gastrointestinal Malignancies Program at the Cleveland Clinic. His clinical and translational research program focuses on new therapeutics and outcomes prediction in gastrointestinal cancers and cancer-associated thrombosis.

    To view Dr. Alok Khorana's publications, visit PubMed